Artificial intelligence-powered precision medicine company Tempus is partnering with pharmaceutical giant Pfizer on a project aiming to advance the use of AI and machine learning capabilities in oncology therapeutic discovery.
Through the partnership, Tempus will grant Pfizer access to its data library, diagnostic offerings and clinical trial matching program, according to a Feb. 28 Tempus news release.
"This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma's deep research and development expertise will get us much closer in realizing the full potential of precision medicine," Tempus founder and CEO Eric Lefkofsky said in the release.